Latest Cormorant Asset Management, LP Stock Portfolio
$1.99Billion– No. of Holdings #46
Cormorant Asset Management, LP Performance:
2026 Q1: -1.13%YTD: -1.13%2025: 40.04%
Performance for 2026 Q1 is -1.13%, and YTD is -1.13%, and 2025 is 40.04%.
About Cormorant Asset Management, LP and 13F Hedge Fund Stock Holdings
Cormorant Asset Management, LP is a hedge fund based in Boston, MA. On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Cormorant Asset Management, LP reported an equity portfolio of $2 Billions as of 31 Mar, 2026.
The top stock holdings of Cormorant Asset Management, LP are PRAX, , EYPT. The fund has invested 14.3% of it's portfolio in PRAXIS PRECISION MEDICINES I and 8% of portfolio in BRIDGEBIO ONCOLOGY THERAPEUT.
The fund managers got completely rid off ENGENE HOLDINGS INC, GH RESEARCH PLC (GHRS) and JANUX THERAPEUTICS INC (JANX) stocks. They significantly reduced their stock positions in ABIVAX SA, AXSOME THERAPEUTICS INC. (AXSM) and INSMED INC (INSM). Cormorant Asset Management, LP opened new stock positions in ERASCA INC (ERAS), DIANTHUS THERAPEUTICS INC and DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to BIOHAVEN LTD, OLEMA PHARMACEUTICALS INC (OLMA) and CABALETTA BIO INC (CABA).
The top stock holdings of Cormorant Asset Management, LP are PRAX, , EYPT. The fund has invested 14.3% of it's portfolio in PRAXIS PRECISION MEDICINES I and 8% of portfolio in BRIDGEBIO ONCOLOGY THERAPEUT.
The fund managers got completely rid off ENGENE HOLDINGS INC, GH RESEARCH PLC (GHRS) and JANUX THERAPEUTICS INC (JANX) stocks. They significantly reduced their stock positions in ABIVAX SA, AXSOME THERAPEUTICS INC. (AXSM) and INSMED INC (INSM). Cormorant Asset Management, LP opened new stock positions in ERASCA INC (ERAS), DIANTHUS THERAPEUTICS INC and DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to BIOHAVEN LTD, OLEMA PHARMACEUTICALS INC (OLMA) and CABALETTA BIO INC (CABA).
Cormorant Asset Management, LP Equity Portfolio Value
Last Reported on: 15 May, 2026
Cormorant Asset Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cormorant Asset Management, LP made a return of -1.13% in the last quarter. In trailing 12 months, it's portfolio return was 78.61%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| erasca inc | 93,844,000 |
| dianthus therapeutics inc | 79,724,000 |
| damora therapeutics inc | 39,497,500 |
| tango therapeutics inc | 29,811,000 |
| agomab therapeutics nv | 25,861,500 |
| maze therapeutics inc | 22,387,500 |
| roivant sciences ltd | 20,775,000 |
| adlai nortye ltd | 20,053,200 |
New stocks bought by Cormorant Asset Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| biohaven ltd | 17,500 |
| olema pharmaceuticals inc | 41.82 |
| bioage labs inc | 41.65 |
| cabaletta bio inc | 25.00 |
| alumis inc | 8.63 |
| moonlake immunotherapeutics | 2.87 |
Additions to existing portfolio by Cormorant Asset Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| abivax sa | -43.7 |
| axsome therapeutics inc. | -33.33 |
| insmed inc | -30.91 |
| bridgebio pharma inc | -29.17 |
| centessa pharmaceuticals plc | -20.75 |
| vaxcyte inc | -20.00 |
| crinetics pharmaceuticals in | -16.67 |
| amylyx pharmaceuticals inc | -12.5 |
Cormorant Asset Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| engene holdings inc | -36,120,000 |
| gh research plc | -16,510,000 |
| janux therapeutics inc | -8,970,000 |
Cormorant Asset Management, LP got rid off the above stocks
Sector Distribution
Cormorant Asset Management, LP has about 55.4% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 55.4 |
| Others | 44.6 |
Market Cap. Distribution
Cormorant Asset Management, LP has about 5.8% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- SMALL-CAP
- LARGE-CAP
- NANO-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 44.6 |
| MID-CAP | 30.4 |
| SMALL-CAP | 14.6 |
| LARGE-CAP | 5.8 |
| NANO-CAP | 2.7 |
| MICRO-CAP | 1.9 |
Stocks belong to which Index?
About 30% of the stocks held by Cormorant Asset Management, LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 70 |
| RUSSELL 2000 | 30 |
Cormorant Asset Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cormorant Asset Management, LP
Cormorant Asset Management, LP has 46 stocks in it's portfolio. About 59.1% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for Cormorant Asset Management, LP last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AMLX | amylyx pharmaceuticals inc | 0.24 | 350,000 | 4,865,000 | reduced | -12.5 | ||
| ARQT | arcutis biotherapeutics inc | 0.53 | 450,000 | 10,602,000 | reduced | -10.00 | ||
| ARWR | arrowhead pharmaceuticals in | 0.32 | 100,000 | 6,270,000 | new | |||
| ASND | ascendis pharma a/s | 1.09 | 95,000 | 21,729,400 | reduced | -5.00 | ||
| AXSM | axsome therapeutics inc. | 0.42 | 50,000 | 8,451,000 | reduced | -33.33 | ||
| BBIO | bridgebio pharma inc | 3.17 | 850,000 | 63,121,000 | reduced | -29.17 | ||
| CABA | cabaletta bio inc | 0.74 | 5,500,000 | 14,795,000 | added | 25.00 | ||
| CNTA | centessa pharmaceuticals plc | 2.10 | 1,050,000 | 41,706,000 | reduced | -20.75 | ||
| CNTX | context therapeutics inc | 0.07 | 529,550 | 1,387,420 | new | |||
| COGT | cogent biosciences inc | 0.39 | 200,000 | 7,698,000 | reduced | -11.11 | ||
| CRBP | corbus pharmaceuticals hldgs | 1.11 | 2,344,970 | 22,019,300 | unchanged | 0.00 | ||
| CRNX | crinetics pharmaceuticals in | 0.46 | 250,000 | 9,080,000 | reduced | -16.67 | ||
| DRUG | bright minds biosciences inc | 3.88 | 1,059,330 | 77,299,400 | unchanged | 0.00 | ||
| ERAS | erasca inc | 4.71 | 5,800,000 | 93,844,000 | new | |||
| EWTX | edgewise therapeutics inc | 5.16 | 3,260,000 | 102,690,000 | reduced | -0.76 | ||
| EYPT | eyepoint inc | 5.35 | 8,265,000 | 106,536,000 | unchanged | 0.00 | ||
| GHRS | gh research plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GLTO | damora therapeutics inc | 1.98 | 1,525,000 | 39,497,500 | new | |||
| GLUE | monte rosa therapeutics inc | 0.33 | 400,000 | 6,580,000 | new | |||
| INSM | insmed inc | 1.56 | 190,000 | 31,068,800 | reduced | -30.91 | ||